Neuroblastoma Market Report 2026

The neuroblastoma market size has grown strongly in recent years. It will grow from $3.14 billion in 2025 to $3.32 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increased prevalence of pediatric neuroblastoma cases, early adoption of chemotherapy treatments, development of immunotherapy vaccines, growth in clinical diagnosis capabilities, rising awareness of childhood cancer symptoms.

The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to expansion of targeted therapy research, increasing investment in cell therapy products, rising adoption of precision oncology methods, development of new pediatric immunotherapy solutions, growth in advanced diagnostic imaging for early detection. Major trends in the forecast period include increasing adoption of immunotherapy vaccines for pediatric cancer, growing use of targeted oral chemotherapy tablets, rising development of monoclonal antibody treatments, expansion of cell therapy and regenerative oncology approaches, increasing focus on early diagnosis and symptom management.

The rising incidence of childhood cancer is expected to drive the growth of the neuroblastoma market in the coming years. Childhood cancer encompasses a range of cancers primarily affecting children and adolescents, often targeting organs such as the brain, blood, and bones, and requiring specialized treatment approaches. Factors contributing to the increasing incidence include improved diagnostic methods, greater awareness, environmental exposures, genetic predispositions, and advances in medical research. Neuroblastoma treatments provide targeted therapies for childhood cancer, enabling early and effective intervention that reduces recurrence risk and improves outcomes for young patients. For example, in May 2024, the American Cancer Society, a US-based professional organization, projected that approximately 9,620 children under 15 in the United States would be diagnosed with cancer in 2024, up from 5,290 cases in 2023. Therefore, the growing incidence of childhood cancer is boosting the neuroblastoma market.

Leading companies in the neuroblastoma market are developing advanced therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to target cancer cells more effectively and safely. These antibodies are engineered to recognize the GD2 molecule on cancer cells while incorporating human components to reduce immune rejection. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. Hu14.18 is designed to treat newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. Under the agreement, Renaissance secured exclusive rights to develop, manufacture, and commercialize Hu14.18 across key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Apeiron Biologics AG for $100 million. This acquisition provides Ligand with royalty rights to Qarziba and expands its commercial royalty portfolio with high-value immunotherapies for high-risk neuroblastoma, supporting growth by generating long-term, predictable revenue from a diversified set of products. Apeiron Biologics AG, based in Austria, develops immunotherapies specifically for neuroblastoma.

Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroblastoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuroblastoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neuroblastoma market by increasing costs for imported chemotherapy tablets, immunotherapy vaccines, and monoclonal antibody formulations essential for pediatric cancer care. Hospitals and clinics in regions heavily dependent on imported oncology drugs - particularly Asia-Pacific and Europe - face higher treatment costs and supply delays. Product categories such as targeted therapy tablets, immunotherapy vaccines, and injectable monoclonal antibodies experience the greatest tariff-driven price fluctuations. However, tariffs are also encouraging domestic pharmaceutical manufacturing and boosting local innovation in pediatric oncology treatments.

The neuroblastoma market research report is one of a series of new reports that provides neuroblastoma market statistics, including neuroblastoma industry global market size, regional shares, competitors with a neuroblastoma market share, detailed neuroblastoma market segments, market trends and opportunities, and any further data you may need to thrive in the neuroblastoma industry. This neuroblastoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuroblastoma is a pediatric cancer that originates from immature nerve cells called neuroblasts and primarily affects the adrenal glands, though it can also develop in the chest, neck, pelvis, or other abdominal regions. This cancer can lead to symptoms such as abdominal pain, swelling, fatigue, and bone pain or palpable lumps.

The main product types used in neuroblastoma treatment include tablets, vaccines, and other therapeutic formulations. Tablets are solid oral doses that contain active pharmaceutical ingredients along with binders and fillers, used to deliver chemotherapy or targeted therapy medications. Neuroblastoma treatments also encompass immunotherapy, radiation therapy, and supportive care. These treatments are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online platforms, and are primarily used by hospitals, pediatric oncology clinics, and specialty treatment centers.

The neuroblastoma market consists of revenues earned by entities by providing services such as diagnosis and imaging, oncology treatment, and stem cell transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroblastoma market also consists of sales of radiopharmaceuticals, monoclonal antibodies, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.